SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The board adopted and stockholders approved an amendment to the 2022 Omnibus Incentive Plan increasing the share reserve by 11,000,000 shares, from 10,033,333 to 21,033,333 shares, expanding equity incentive capacity for officers and directors.
View raw filing on EDGAR →The filing discloses an amendment to the Severance and Change in Control Agreement with CEO Richard Wilmer that removes the scheduled termination date and extends the agreement indefinitely until his separation. This is a material modification to compensatory and severance arrangements for a named executive officer, fitting the exec_compensation category. While the amendment does not involve a departure or appointment, it materially alters the CEO's severance protections and contingent compensation rights.
View raw filing on EDGAR →The Company issued 31,948 unregistered restricted shares to four independent directors as compensation for board service pursuant to the Independent Director Compensation Plan, with an aggregate value of $384,973.40 and vesting conditions tied to board service.
View raw filing on EDGAR →The disclosure centers on approval of a Discretionary Credit Award Agreement for Adam Heflin, a named executive officer, providing $1.5 million in discretionary credits vested over multiple years under the Deferred Compensation Plan. This is a compensatory arrangement—specifically an equity/deferred compensation award—not a departure or appointment. The material amount and multi-year vesting schedule make this material to investors.
View raw filing on EDGAR →This exhibit is a comprehensive Statement of Executive Compensation disclosing the compensation arrangements, policies, and awards for Mako Mining's named executive officers (CEO Akiba Leisman, CFO Ezequiel Sirotinsky, President Stephen Parsons, COO Jesse Munoz, and VP Exploration Frank Powell) for fiscal year 2025. It details base salaries, annual bonuses, equity-based awards (RSUs, DSUs, Options), performance metrics, and governance policies including a newly adopted clawback policy effective February 23, 2026. The Summary Compensation Table shows total compensation ranging from $676,717 to $2,623,649 across the NEOs, making this a material disclosure of executive compensation arrangements and awards.
View raw filing on EDGAR →The filing discloses compensatory arrangements for three named executives: salary increases (retroactive to April 1, 2026) for Serhii Kupriienko (CEO Global) from $250,000 to $375,000, Alexander Fink (CEO U.S. and President) from $250,000 to $375,000, and Brooks Ensign (CFO) from $250,000 to $300,000, along with target annual bonuses of 100%, 100%, and 50% of base salary respectively. These are material changes to executive compensation approved by the Compensation Committee and Board.
View raw filing on EDGAR →The Board approved amendments to employment agreements for three named executives (Christopher Giordano, Thomas Staab, and Stuart Rich) modifying their severance and change-in-control benefits, including base salary continuation, bonus payments, equity acceleration, and COBRA reimbursements. Concurrently, the Board adopted a Change in Control Plan and a Severance Plan establishing compensatory arrangements for eligible employees with similar benefits.
View raw filing on EDGAR →The disclosure centers on compensatory arrangements for two interim executives: approval of Mr. Rothstein's salary of $30,000 per month and entry into an employment agreement with Mr. Weinmann specifying base salary of $300,000 per year, discretionary bonus structure, and severance terms. While the Item 5.02 heading also covers appointments, the substantive focus here is on the compensation terms approved and agreed to on June 24, 2026, making this primarily an exec_compensation event rather than exec_appointment (which was previously announced on June 16).
View raw filing on EDGAR →The filing discloses multiple compensatory arrangements approved by the HRCC effective June 24, 2026: (1) a TY26 annual cash incentive plan with target payouts ranging from 100–175% of base salary for six named executive officers; (2) a TY26–CY28 long-term equity program comprising PSUs and RSUs with target payouts of 200–450% of base salary; (3) Spin-Off bonuses (cash and RSUs) totaling up to $1 million for Mr. Smith; and (4) an Equity-Based Retirement Policy governing vesting treatment. These are core executive compensation matters within the scope of Item 5.02(e).
View raw filing on EDGAR →Ronald L. Sargent transitioned from Chief Executive Officer to Non-Executive Chairman with a new compensatory arrangement consisting of an annual retainer of $115,000 and incentive share grants valued at approximately $250,000.
View raw filing on EDGAR →The disclosure centers on compensatory arrangements for Jim Stephens, the Company's President of Cardiac Rhythm Management & Neuromodulation, including approval by the Compensation and Organization Committee of changes to his compensation in connection with a role transition to Executive Vice President, Special Projects, effective June 29, 2026, with a termination date of March 31, 2027, and exclusion from short-term and long-term incentive awards in 2027. While the filing also involves a role change, the principal disclosed action and the Committee's formal approval focus on the compensation modifications and severance-related terms (including the conditional "termination without Cause" treatment under the Change of Control Agreement), making this primarily a compensatory arrangement disclosure under Item 5.02(e).
View raw filing on EDGAR →This exhibit is a written board resolution approving one-time performance bonuses for two named executives: Ms. Zhang Fan (Business Development Director) receives US$200,000 and Mr. Fu Xiaowei (CEO and Executive Director) receives US$300,000 for services rendered during 2025. The bonuses may be paid in cash or equivalent Class A ordinary shares. This is a direct disclosure of compensatory arrangements for named executives, fitting the exec_compensation category.
View raw filing on EDGAR →The Compensation Committee approved on June 22, 2026, a special leadership retention performance share award of 25,000 Performance Shares each for four named executives (Colin J. Souza, Patrick J. Kennedy, Steven M. Caravati, and James R. Bowes), subject to performance-based vesting conditions tied to adjusted EBITDA and return on assets targets for fiscal 2027–2030 and a retention condition.
View raw filing on EDGAR →Stockholders approved an amendment to the Myomo 2018 Stock Option and Incentive Plan increasing available shares by 1,833,000, expanding the pool of equity grants available to officers and directors.
View raw filing on EDGAR →This announcement discloses a grant of 1,890,627 restricted share units (RSUs) to certain employees of Bilibili Inc. pursuant to the Second Amended and Restated 2018 Share Incentive Plan on June 26, 2026. The grant represents approximately 0.45% of total shares outstanding and includes vesting schedules (June 2027–2030) and clawback provisions. This is a compensatory arrangement for employees and falls squarely within exec_compensation disclosure requirements, as it involves equity grants to incentivize and retain key personnel.
View raw filing on EDGAR →The Item 5.02 disclosure centers on two compensatory arrangements: (1) a new Executive Placement Agreement with SBR Limited for COO Jeroen Nieuwkoop providing $400,000 annual base salary, discretionary bonus up to 100% of base, and $1,000,000 annual equity awards plus $2,000,000 in initial RSU grants; and (2) a First Amendment to CEO David Schamis's employment agreement increasing his base salary to $600,000 and providing annual equity awards of $2,000,000–$3,000,000. These are material compensatory arrangements affecting named executives, not departures or appointments of new individuals.
View raw filing on EDGAR →The disclosure centers on a $4 million retention bonus agreement with Artem Yegorov, the Chief Technology Officer, contingent on his continued employment through the fourth anniversary of the effective date. This is a compensatory arrangement for a named executive officer, fitting the exec_compensation category. The materiality is clear given the size of the bonus and its strategic importance to retaining a key technology executive.
View raw filing on EDGAR →HeartSciences issued unregistered equity securities as compensatory awards to officers or directors, with the disclosure incorporating Item 5.02 by reference and relying on officer/director representations regarding the exemption.
View raw filing on EDGAR →The filing discloses amendments to compensatory arrangements for three named executives: Dr. Angelos Stergiou (President and CEO), John Burns (Senior Vice President and CFO), and Dr. Dragan Cicic (Senior Vice President and Chief Development Officer). The amendments modify severance and change-of-control benefits, including lump-sum payments, extended severance periods (9-18 months), bonus provisions, COBRA reimbursement, and equity acceleration upon termination. These are classic executive compensation arrangements subject to Item 5.02(e) disclosure and would materially affect investor assessment of executive retention costs and change-of-control obligations.
View raw filing on EDGAR →The Compensation Committee approved material changes to CFO John North's compensation package, including: (i) a base salary increase from $175,000 to $275,000 effective October 1, 2026; (ii) confirmation of a 100% annual target bonus opportunity; and (iii) modification of a market condition performance-vesting RSU arrangement with potential grants totaling up to $19.1 million ($1.6M + $7M + $10.5M) upon achievement of specified market capitalization, stock price, or EBITDA thresholds, plus additional change-of-control provisions. This is a classic executive compensation disclosure under Item 5.02(e).
View raw filing on EDGAR →The disclosure centers on amended and restated employment agreements for two named executives (CFO Conor Fennerty and Chief Investment Officer John Cattonar) that materially modify their compensation packages, including base salary increases ($600K→$650K and $500K→$550K), specified equity award targets (performance-based and time-based), and substantial backloaded restricted stock grants ($1.5M and $1.37M respectively with five-year vesting). This is a classic compensatory arrangement disclosure under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →The combined company approved and implemented three equity incentive plans: the 2026 Incentive Award Plan (5,039,004 shares, 7% of post-Closing shares), the 2026 Employee Stock Purchase Plan (1,439,715 shares, 2% of post-Closing shares), and assumed the 2020 Equity Incentive Plan, all designed to attract and retain key personnel and approved by shareholders on June 16, 2026.
View raw filing on EDGAR →The Compensation Committee approved material changes to CEO Brent Lucas's compensation package, including an updated base salary of $420,000, a targeted cash bonus of $105,000, and equity grants of 1,000,000 stock options and 1,000,000 RSUs with performance-based vesting tied to FDA approval of the Acclaim cochlear implant. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →The filing discloses issuance of 25,000 shares of common stock to Bill Dyer, Chief Operating Officer, as a "transaction achievement bonus" pursuant to the Company's 2024 equity incentive plan, approved by the Board on June 16, 2026. This is a compensatory arrangement for a named executive officer under Item 5.02(e). The bonus is material as it represents equity compensation tied to a merger transaction (the XTEND Reality Expansion Ltd. agreement dated February 13, 2026).
View raw filing on EDGAR →The Compensation Committee approved cash retention bonus awards to named executive officers (Kim Kelderman, Jim Hippel, William Geist, Shane Bohnen, and Steve Crouse) totaling approximately $6.7 million, contingent on the contemplated Merger, including associated tax gross-up provisions.
View raw filing on EDGAR →The Company amended and restated executive employment agreements for CEO James Rolke and CFO Chester S. Zygmont, III, effective June 24, 2026, increasing change-in-control severance benefits to 2x base salary plus target bonus with COBRA reimbursement up to 18 months, expanding flexibility for outside activities, and establishing a three-year initial term with automatic renewal.
View raw filing on EDGAR →The filing discloses compensatory arrangements for two named executives: Dr. Hartnett's new employment agreement (effective June 23, 2026) with a 3.0% base salary increase to $1,591,350 and modifications to performance-based compensation and equity award sizing; and Mr. Bergeron's amendment to his employment agreement with a 3.0% base salary increase to $713,482 and similar equity award modifications. These are classic Item 5.02(e) executive compensation disclosures affecting material terms of employment for senior officers.
View raw filing on EDGAR →The 6-K discloses a Parachute Agreement (severance arrangement) entered into on June 19, 2026 between Genenta Science and Pierluigi Paracchi, the CEO and General Manager. The agreement specifies severance payments upon qualifying termination events (twelve months of gross remuneration plus target annual bonus up to 40% of annual gross remuneration), which constitutes a material compensatory arrangement for a named executive officer. While the filing also mentions an amendment to a non-compete covenant, the primary disclosure is the severance/parachute agreement, which falls squarely within executive compensation disclosures (Item 5.02(e) equivalent).
View raw filing on EDGAR →CAVA Group amended its Executive Severance Plan with material changes to eligibility, severance benefit conditions, offset provisions, and change-of-control standstill periods, affecting compensatory arrangements for directors and officers.
View raw filing on EDGAR →The disclosure centers on amended and restated employment and change of control agreements for five named officers (Van Dyke, Langs, Bell, Speare, and Kallsen), updating their compensatory arrangements and severance terms to comply with new Virginia law effective July 1, 2026, and reflecting current base salaries and positions. This is a classic Item 5.02(e) compensatory arrangement disclosure, distinct from a departure or appointment, and material because it modifies severance, clawback, and restrictive covenant provisions for senior executives.
View raw filing on EDGAR →The disclosure centers on amended and restated employment agreements for two named executives (Ryan R. Smith and Jamie M. Schnur) that modify their compensatory arrangements, including severance multiples, payment periods, and post-employment benefits. While the agreements also address termination conditions, the principal disclosed action is the modification of executive compensation terms—specifically reducing Mr. Smith's severance multiple from 3x to 2x base salary and shortening restrictive covenant periods from 36 to 24 months. This is a classic exec_compensation event under Item 5.02(e).
View raw filing on EDGAR →The Board approved amended compensation arrangements for non-employee directors, including increases to annual cash retainers (base retainer increased $5,000 to $80,000; committee chair retainers increased $2,500–$5,000; Board Chair retainer increased $5,000 to $60,000) and restricted stock unit awards (base award increased $15,000 to $140,000; Board Chair award increased $10,000 to $70,000). This is a material compensatory arrangement disclosure under Item 5.02(e), affecting director compensation structure and equity grants.
View raw filing on EDGAR →Stockholders approved and adopted the FibroBiologics, Inc. 2026 Equity and Incentive Compensation Plan, which authorizes 2,061,968 shares and enables the Compensation Committee to grant equity-based and cash-based compensation to employees, officers, consultants, and directors, including performance-based awards and evergreen provisions.
View raw filing on EDGAR →The filing discloses Item 5.02 approval by the Compensation Committee of one-time special discretionary cash bonus awards to the CEO ($250,000) and CFO ($100,000), explicitly recognizing their contributions to the Company's NYSE American listing, strategic repositioning toward AI/HPC infrastructure, and data center pipeline development. This is a compensatory arrangement for named executives, distinct from a departure or appointment.
View raw filing on EDGAR →This Item 5.02(e) disclosure describes grants of restricted stock units (RSUs) and performance-based restricted stock units (PBRSUs) to named executives including CEO J. Douglas Schick (22,830 RSUs + 15,220 PBRSUs), EVP/General Counsel Clark Moore (18,950 RSUs + 5,270 PBRSUs), Chief Commercial Officer Jody Crook (16,050 RSUs + 7,020 PBRSUs), and other employees, approved by the Compensation Committee as part of the 2025 annual compensation review. This is a classic compensatory arrangement disclosure under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →The 6-K discloses a Board-approved amendment to the Mynd.ai Equity Incentive Plan on June 17, 2026, increasing available shares by 106,000,000 Ordinary Shares. This is a material amendment to a compensatory arrangement affecting equity grants to directors, officers, and employees. The substantial one-time increase to the equity pool, combined with the existing evergreen provision, materially expands the Company's capacity to grant equity awards and would affect investor assessment of dilution and executive compensation practices.
View raw filing on EDGAR →Stockholders approved an amendment and restatement of the Company's 2000 Long-Term Incentive Plan, which reserves 10,717,500 shares for issuance as stock options, restricted stock, deferred stock, and other awards to directors, officers, and employees.
View raw filing on EDGAR →This exhibit is a supplemental letter to Tower's proxy statement seeking shareholder approval of an amended and restated compensation policy for directors and executive officers under Israeli law. The letter details proposed changes to compensation arrangements, including increases to CEO maximum annual bonus (175% to 225% of salary), CEO equity award limits (10x to 13x salary), and other executive officer compensation caps. These are material compensatory arrangements requiring shareholder approval under Section 5.02(e) of the 8-K taxonomy and Israeli corporate governance law.
View raw filing on EDGAR →The disclosure centers on a new employment agreement with CEO Ramesh Srinivasan that establishes compensatory arrangements: a $600,000 base salary, annual bonus eligibility up to 150% of base salary, and a substantial $6.8 million RSU grant (78,269 units) with both time-based and performance-based vesting conditions tied to stock price targets ($105–$135 per share). The agreement also specifies severance and change-of-control provisions. This is a material executive compensation arrangement under Item 5.02(e).
View raw filing on EDGAR →Stockholders approved amendments to the Company's 2015 Equity Incentive Plan (increasing authorized shares by 6.5 million) and the Employee Stock Purchase Plan (increasing authorized shares by 1 million), expanding the pool of shares available for equity compensation and employee stock purchase eligibility.
View raw filing on EDGAR →The disclosure centers on compensatory arrangements approved by the Compensation Committee for Branislav Vajdic, the Company's President and Founder, including a 2.8 million PRSU award under the 2022 Equity Incentive Plan and a transaction bonus agreement tied to change-of-control milestones. This is a classic exec_compensation event under Item 5.02(e), distinct from appointment or departure, and is material given the substantial equity grant and transaction-contingent bonus to a named executive officer.
View raw filing on EDGAR →The filing discloses under Item 5.02 that the board approved annual compensation of $150,000 for Dr. Amy T. Clemens, who was recently appointed as Chief Financial Officer on June 4, 2026. While the appointment itself occurred previously, the principal disclosed action in this 8-K is the board's approval of her compensatory arrangement, making this an executive compensation disclosure rather than an appointment event.
View raw filing on EDGAR →The disclosure announces a new CEO contract for Michael O'Leary extending to April 2032, including a modest annual salary, capped annual bonus, and a one-off equity purchase option over 10 million shares with performance-based vesting conditions tied to PAT growth (€4.0bn) or share price targets (€42 or $102). This is a material compensatory arrangement for a named executive officer that would affect investor assessment of executive incentives and long-term leadership continuity.
View raw filing on EDGAR →This 6-K discloses a grant of 10 million share options to Michael O'Leary, Group Chief Executive Officer, at a strike price of €26.70 under the Ryanair Holdings plc 2019 Long Term Incentive Plan. This is a compensatory arrangement for a named executive officer and falls squarely within exec_compensation disclosure requirements under Article 19 of the EU Market Abuse Regulation. The materiality is high given the size of the grant (10 million options) and the executive's senior position.
View raw filing on EDGAR →Stockholders approved the Hawkeye Digital, Inc. 2026 Equity Incentive Plan, a compensatory arrangement designed to provide equity incentives to employees, consultants, and directors.
View raw filing on EDGAR →The disclosure centers on a Third Amended and Restated Employment Agreement with John H. Tyson, the Chairman, detailing comprehensive compensatory arrangements including a $3.5M annual base salary, 300% target annual incentive, $6M long-term incentive grants, a $40M one-time cash payment, aircraft use, personal security services, and severance provisions. This is a material executive compensation arrangement requiring 8-K disclosure under Item 5.02(e).
View raw filing on EDGAR →The Board approved and stockholders ratified amendments to the Willdan Group 2008 Performance Incentive Plan, including a 380,000-share increase in available awards and extension of the plan term to 2036, materially affecting future dilution and executive compensation capacity.
View raw filing on EDGAR →The filing discloses multiple compensatory arrangements approved by the Board on June 18, 2026: (1) an updated non-employee director compensation program with specified annual cash retainers; (2) a $5.0 million change-in-control Retention and Incentive Plan with annual CPI-U adjustments; (3) a performance-based Waterfall Merger Incentive Program tied to IRR thresholds; and (4) confirmation of vesting of 35,419 RSUs under the 2020 LTIP. These are material compensation arrangements that would affect investor assessment of executive incentives and retention structures.
View raw filing on EDGAR →This exhibit discloses a partial amendment to Toyota's share-based compensation plan for employees in "Senior Professional / Senior Management (Kanbushoku)" positions. The amendments modify vesting dates (from "first business day of August immediately following retirement" to "the date on which the Eligible Employee retires") and add provisions for employees becoming residents of countries not covered by the Plan. These changes materially affect the compensatory arrangements and timing of equity delivery for named executives and senior management, falling squarely within the exec_compensation category.
View raw filing on EDGAR →The filing discloses adoption of new forms of equity award agreements (RSU, stock option, and common stock agreements) under the 2021 Incentive Award Plan and grants of time-based RSUs to three named executive officers (Dave Lillis, Jeff Mayfield, and Ryan Salmons) totaling approximately $319,636 in aggregate grant-date fair value. Item 5.02(e) explicitly identifies these as "material compensatory arrangements," and the disclosure details vesting structures, fair values, and vesting commencement dates for each executive.
View raw filing on EDGAR →